
Qualcomm says it has struck a deal, of sorts, with four major smartphone vendors in China that could possibly be worth US$12 billion.
The chip designer says the non-binding “memorandum of understanding” agreements will bring Xiaomi, Guangdong OPPO, and Vivo Communications to the table in an attempt to hammer out licensing deals to use Qualcomm chips in its mobile phone designs.
The announcement was made as part of President Trump’s visit to China, where Qualcomm CEO Steve Mollenkopf attended as part of the White House trade delegation tagging along for the trip.
“I’m honored to represent Qualcomm as part of this important trade delegation, which showcases the importance of win-win business relationships between the US and China,” Mollenkopf said of the memo.
“Qualcomm has longstanding relationships with Xiaomi, OPPO and Vivo and we are continuing our commitment to investing and helping advance China’s mobile and semiconductor industries.”
The deal would potentially be a boon for Qualcomm in a country where it has had trouble with both customers and government officials in the past. Qualcomm has struggled for years to extract the patent fees it believes Chinese electronics companies owed for using its designs, though more recently it has touted progress in collecting some of what it feels it’s due.
Full Content: San Diego Union Tribune
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas